Pfizer has received regulatory approval in China for its GLP-1 receptor agonist drug Xianweiying, marking the company’s entry into the country’s rapidly growing market for weight-management treatments.

The injectable therapy has been cleared for long-term weight management in overweight or obese adults, according to an announcement from the company’s China operations.

Competition Intensifies in GLP-1 Market

The treatment belongs to the GLP-1 receptor agonist class of drugs, a category that has rapidly transformed the global obesity treatment market.

Major pharmaceutical players already operating in the Chinese market include Novo Nordisk and Eli Lilly, whose GLP-1 medications have seen surging global demand.

Chinese biotech firms are also active in the space, including Innovent Biologics, whose locally developed obesity treatment has gained traction among patients.

Analysts expect the obesity treatment market in China to grow into a multibillion-dollar industry in the coming years as demand for effective weight-loss medications rises.

Licensing Deal Enabled China Entry

Pfizer secured commercialization rights for the drug in mainland China through a licensing agreement with Sciwind Biosciences earlier this year.

Sciwind developed the drug, also known as ecnoglutide, and licensed its marketing rights in mainland China to Pfizer as part of the pharmaceutical giant’s strategy to expand its presence in metabolic disease treatments.

The biotech company described the approval as a major milestone in the field of weight management.

Drug Already Used for Diabetes Treatment

Ecnoglutide is already approved in China as a treatment for Type 2 Diabetes, allowing physicians to use the therapy in managing blood glucose levels before its new authorization for obesity treatment.

The expanded approval enables the drug to compete directly in China’s growing GLP-1 therapy market, which includes blockbuster medications such as Wegovy.

According to investment research estimates, online sales of GLP-1 treatments through Chinese e-commerce platforms have already reached hundreds of millions of yuan annually.

Launch Details Still Pending

While the regulatory approval marks a major step forward, Pfizer has not yet disclosed pricing or an official launch timeline for the product in China.

Market analysts expect competition among pharmaceutical companies to intensify as more obesity treatments enter the Chinese healthcare system.